Mills GB - Search Results

1

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ. Zhang Y, et al. Among authors: mills gb. Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18. Cancer Cell. 2017. PMID: 28528867 Free PMC article.

2

Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.

Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Davies MA, et al. Among authors: mills gb. Cancer Res. 1998 Dec 1;58(23):5285-90. Cancer Res. 1998. PMID: 9850049

3

Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase.

Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch K, Mills GB. Cuevas BD, et al. Among authors: mills gb. J Biol Chem. 2001 Jul 20;276(29):27455-61. doi: 10.1074/jbc.M100556200. Epub 2001 May 3. J Biol Chem. 2001. PMID: 11337495 Free article.

4

Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy.

Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z. Liang K, et al. Among authors: mills gb. Mol Cancer Ther. 2003 Apr;2(4):353-60. Mol Cancer Ther. 2003. PMID: 12700279

5

Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.

Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Lu Y, et al. Among authors: mills gb. J Biol Chem. 2003 Oct 10;278(41):40057-66. doi: 10.1074/jbc.M303621200. Epub 2003 Jul 17. J Biol Chem. 2003. PMID: 12869565 Free article.

6

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Mills GB, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):93-104. doi: 10.1053/j.seminoncol.2003.08.011. Semin Oncol. 2003. PMID: 14613030 Review.

7

Targeting PI3K-AKT pathway for cancer therapy.

Lu Y, Wang H, Mills GB. Lu Y, et al. Among authors: mills gb. Rev Clin Exp Hematol. 2003 Jun;7(2):205-28. Rev Clin Exp Hematol. 2003. PMID: 14763163 Review.

8

The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.

Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. Mandal M, et al. Among authors: mills gb. Br J Cancer. 2005 May 23;92(10):1899-905. doi: 10.1038/sj.bjc.6602595. Br J Cancer. 2005. PMID: 15870708 Free PMC article. Retracted.

9

WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome.

Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, Aldaz CM. Nunez MI, et al. Among authors: mills gb. BMC Cancer. 2005 Jun 27;5:64. doi: 10.1186/1471-2407-5-64. BMC Cancer. 2005. PMID: 15982416 Free PMC article.

10

Exploiting the PI3K/AKT pathway for cancer drug discovery.

Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Hennessy BT, et al. Among authors: mills gb. Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. doi: 10.1038/nrd1902. Nat Rev Drug Discov. 2005. PMID: 16341064 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,137 results

Search Page